Amneal Rebukes Teva’s Patent Delisting Concerns as Unwarranted Drama

Amneal Pharmaceuticals has criticized Teva Pharmaceuticals’ reaction to a recent legal challenge surrounding its inhaler patents, describing it as a “theatrical distraction.” This comes following a court order requiring Teva to remove certain patents from the U.S. Food and Drug Administration’s Orange Book. Amneal claims that the pharmaceutical industry will not experience “chaos and disruption” if the Federal Circuit court does not suspend the injunction, countering Teva’s dire predictions. For further details on the ongoing legal developments, the article on Law360 discusses the nuances of Amneal’s stance and the implications for both companies in the pharmaceuticals sector.